91 phenotypes from 5 alleles in 7 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Asxl1tm1.1Iaai/Asxl1tm1.1Iaai Tg(Mx1-cre)1Cgn/0 involves: 129S/SvEv * C57BL/6 * CBA	abnormal myelopoiesis	J:208092
	decreased hemoglobin content	J:208092
	decreased leukocyte cell number	J:208092
	decreased mature B cell number	J:208092
	decreased monocyte cell number	J:208092
	decreased neutrophil cell number	J:208092
	extramedullary hematopoiesis	J:208092
	increased erythroid progenitor cell number	J:208092
	increased nucleated erythrocyte cell number	J:208092
Asxl1tm1.1Iaai/Asxl1tm1.1Iaai Tg(VAV1-cre)1Graf/0 involves: 129S/SvEv * C57BL/6	abnormal definitive hematopoiesis	J:208092
	abnormal hematopoietic stem cell morphology	J:208092
	abnormal myelopoiesis	J:208092
	anemia	J:208092
	decreased bone marrow cell number	J:208092
	decreased hemoglobin content	J:208092
	decreased leukocyte cell number	J:208092
	decreased mature B cell number	J:208092
	decreased monocyte cell number	J:208092
	decreased neutrophil cell number	J:208092
	decreased splenocyte number	J:208092
	increased erythroid progenitor cell number	J:208092
	increased hematopoietic stem cell number	J:208092
	increased nucleated erythrocyte cell number	J:208092
Asxl1tm1.1Mjxu/Asxl1+ involves: 129 * C57BL/6	abnormal blood cell morphology/development	J:208085
	abnormal bone marrow cell morphology/development	J:208085
	abnormal common myeloid progenitor cell morphology	J:208085
	abnormal leukocyte morphology	J:208085
	abnormal liver morphology	J:208085
	abnormal myelopoiesis	J:208085
	abnormal neutrophil morphology	J:208085
	abnormal neutrophil physiology	J:208085
	abnormal spleen morphology	J:208085
	anemia	J:208085
	decreased B cell number	J:208085
	decreased hematopoietic stem cell number	J:208085
	decreased leukocyte cell number	J:208085
	decreased neutrophil cell number	J:208085
	enlarged liver	J:208085
	enlarged spleen	J:208085
	increased apoptosis	J:208085
	increased cell proliferation	J:208085
	increased hematopoietic stem cell number	J:208085
	increased leukemia incidence	J:208085
	increased leukocyte cell number	J:208085
	increased malignant tumor incidence	J:208085
	increased monocyte cell number	J:208085
	increased sarcoma incidence	J:208085
	polychromatophilia	J:208085
	premature death	J:208085
	thrombocytopenia	J:208085
Asxl1tm1.1Mjxu/Asxl1tm1.1Mjxu involves: 129 * C57BL/6	abnormal common myeloid progenitor cell morphology	J:208085
	abnormal hematopoietic stem cell physiology	J:208085
	abnormal leukocyte morphology	J:208085
	abnormal megakaryocyte morphology	J:208085
	abnormal neutrophil morphology	J:208085
	abnormal spleen white pulp morphology	J:208085
	anemia	J:208085
	anophthalmia	J:208085
	decreased B cell number	J:208085
	decreased body size	J:208085
	decreased body weight	J:208085
	decreased erythroid progenitor cell number	J:208085
	decreased hematopoietic stem cell number	J:208085
	decreased leukocyte cell number	J:208085
	decreased lymphocyte cell number	J:208085
	decreased spleen red pulp amount	J:208085
	decreased spleen weight	J:208085
	impaired hematopoiesis	J:208085
	increased apoptosis	J:208085
	increased bone marrow cell number	J:208085
	increased cell proliferation	J:208085
	increased monocyte cell number	J:208085
	increased number of Howell-Jolly bodies	J:208085
	increased single-positive T cell number	J:208085
	lethality throughout fetal growth and development, incomplete penetrance	J:208085
	myeloid hyperplasia	J:208085
	neonatal lethality, incomplete penetrance	J:208085
	polychromatophilia	J:208085
	postnatal lethality, incomplete penetrance	J:208085
	premature death	J:208085
	small spleen	J:208085
	spleen atrophy	J:208085
	thrombocytopenia	J:208085
Asxl1tm1.2Iaai/Asxl1+ involves: 129S/SvEv * C57BL/6	abnormal craniofacial morphology	J:208092
Asxl1tm1.2Iaai/Asxl1tm1.2Iaai involves: 129S/SvEv * C57BL/6	abnormal hyoid bone morphology	J:208092
	abnormal skeleton morphology	J:208092
	anophthalmia	J:208092
	cleft palate	J:208092
	lethality throughout fetal growth and development, complete penetrance	J:208092
	mandible hypoplasia	J:208092
	microphthalmia	J:208092
	vertebral transformation	J:208092
Asxl1tm1a(EUCOMM)Wtsi/Asxl1+ B6Dnk;B6Brd;B6N-Asxl1tm1a(EUCOMM)Wtsi Tyrc-Brd/WtsiH	abnormal cornea morphology	J:175295
	corneal opacity	J:175295
	decreased circulating glucose level	J:175295
	decreased hemoglobin content	J:175295
	decreased leukocyte cell number	J:175295
	decreased lumbar vertebrae number	J:175295
	decreased mean corpuscular hemoglobin	J:175295
	increased blood uric acid level	J:175295
	increased sacral vertebrae number	J:175295
	vertebral fusion	J:175295
Asxl1tm1a(EUCOMM)Wtsi/Asxl1+ C57BL/6N-Asxl1tm1a(EUCOMM)Wtsi/Cnrm	abnormal coping response	J:165965
	decreased B cell number	J:165965
	decreased circulating free fatty acids level	J:165965
	decreased circulating triglyceride level	J:165965
	increased circulating alkaline phosphatase level	J:165965
	increased circulating iron level	J:165965
	increased mean corpuscular hemoglobin concentration	J:165965
Asxl1tm1a(EUCOMM)Wtsi/Asxl1+ involves: C57BL/6N	eye opacity	J:200082
	increased opacity of vitreous body	J:200082
Asxl1tm1a(EUCOMM)Wtsi/Asxl1tm1a(EUCOMM)Wtsi involves: C57BL/6N	lethality, complete penetrance	J:200082
Asxl1tm1Bc/Asxl1tm1Bc involves: 129P2/OlaHsd * C57BL/6J	abnormal blood cell morphology/development	J:155898
	abnormal common myeloid progenitor cell morphology	J:155898
	abnormal immune system cell morphology	J:155898
	abnormal immune system organ morphology	J:155898
	abnormal lymphopoiesis	J:155898
	abnormal thymus morphology	J:155898
	decreased B cell number	J:155898
	decreased bone marrow cell number	J:155898
	decreased CD4-positive, alpha-beta T cell number	J:155898
	decreased pre-B cell number	J:155898
	decreased T cell number	J:155898
	extramedullary hematopoiesis	J:155898
	increased double-negative T cell number	J:155898
	spleen hyperplasia	J:155898